Compare TALK & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TALK | OMER |
|---|---|---|
| Founded | 2012 | 1994 |
| Country | United States | United States |
| Employees | 521 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 788.5M | 772.8M |
| IPO Year | N/A | 2008 |
| Metric | TALK | OMER |
|---|---|---|
| Price | $5.20 | $10.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $6.42 | ★ $32.50 |
| AVG Volume (30 Days) | 1.3M | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | N/A | ★ 0.62 |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | $26.02 | N/A |
| Revenue Next Year | $21.24 | $233.22 |
| P/E Ratio | $155.55 | ★ $17.95 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.22 | $2.95 |
| 52 Week High | $5.20 | $17.65 |
| Indicator | TALK | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 55.78 | 33.80 |
| Support Level | $4.59 | $10.82 |
| Resistance Level | $5.20 | $12.06 |
| Average True Range (ATR) | 0.01 | 0.83 |
| MACD | -0.00 | -0.32 |
| Stochastic Oscillator | 50.50 | 12.73 |
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.